Zymeworks Inc. (NYSE:ZYME) Director Ecor1 Capital, Llc Acquires 196,438 Shares

Zymeworks Inc. (NYSE:ZYME - Get Free Report) Director Ecor1 Capital, Llc purchased 196,438 shares of the stock in a transaction that occurred on Friday, April 4th. The stock was purchased at an average price of $11.17 per share, for a total transaction of $2,194,212.46. Following the acquisition, the director now owns 17,699,774 shares in the company, valued at approximately $197,706,475.58. This trade represents a 1.12 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link.

Ecor1 Capital, Llc also recently made the following trade(s):

• On Wednesday, April 2nd, Ecor1 Capital, Llc purchased 74,360 shares of Zymeworks stock. The shares were purchased at an average cost of $11.85 per share, with a total value of $881,166.00.
• On Monday, March 31st, Ecor1 Capital, Llc bought 4,397 shares of Zymeworks stock. The shares were acquired at an average price of $11.75 per share, with a total value of $51,664.75.
• On Wednesday, March 26th, Ecor1 Capital, Llc purchased 43,848 shares of Zymeworks stock. The stock was acquired at an average cost of $12.24 per share, for a total transaction of $536,699.52.
• On Monday, March 24th, Ecor1 Capital, Llc acquired 22,689 shares of Zymeworks stock. The shares were acquired at an average cost of $13.08 per share, with a total value of $296,772.12.
• On Friday, March 21st, Ecor1 Capital, Llc bought 31,033 shares of Zymeworks stock. The stock was bought at an average cost of $12.78 per share, for a total transaction of $396,601.74.
• On Wednesday, March 19th, Ecor1 Capital, Llc purchased 58,306 shares of Zymeworks stock. The shares were bought at an average cost of $12.64 per share, with a total value of $736,987.84.
• On Monday, March 17th, Ecor1 Capital, Llc bought 56,277 shares of Zymeworks stock. The stock was purchased at an average cost of $12.23 per share, with a total value of $688,267.71.
• On Thursday, March 13th, Ecor1 Capital, Llc acquired 468,356 shares of Zymeworks stock. The stock was purchased at an average cost of $12.48 per share, with a total value of $5,845,082.88.
• On Tuesday, March 11th, Ecor1 Capital, Llc purchased 320,690 shares of Zymeworks stock. The shares were acquired at an average cost of $11.49 per share, for a total transaction of $3,684,728.10.
• On Friday, January 17th, Ecor1 Capital, Llc bought 19,748 shares of Zymeworks stock. The shares were acquired at an average price of $13.87 per share, for a total transaction of $273,904.76.

Zymeworks Price Performance

NYSE ZYME traded up $1.19 on Friday, reaching $10.63. The company had a trading volume of 1,129,355 shares, compared to its average volume of 621,132. Zymeworks Inc. has a 1 year low of $7.97 and a 1 year high of $17.70. The firm has a 50-day moving average of $12.68 and a 200-day moving average of $13.57. The firm has a market capitalization of $739.60 million, a PE ratio of -7.09 and a beta of 1.18.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Deutsche Bank AG increased its stake in Zymeworks by 1.2% during the 4th quarter. Deutsche Bank AG now owns 1,546,772 shares of the company's stock worth $22,645,000 after buying an additional 17,849 shares during the period. State Street Corp grew its stake in shares of Zymeworks by 6.1% during the third quarter. State Street Corp now owns 1,171,777 shares of the company's stock valued at $14,706,000 after acquiring an additional 67,401 shares in the last quarter. Dimensional Fund Advisors LP increased its position in shares of Zymeworks by 14.5% during the fourth quarter. Dimensional Fund Advisors LP now owns 972,742 shares of the company's stock worth $14,240,000 after acquiring an additional 123,240 shares during the last quarter. Bridgeway Capital Management LLC lifted its stake in shares of Zymeworks by 2.3% in the fourth quarter. Bridgeway Capital Management LLC now owns 759,653 shares of the company's stock worth $11,121,000 after acquiring an additional 17,092 shares in the last quarter. Finally, Assenagon Asset Management S.A. boosted its holdings in Zymeworks by 93.9% in the fourth quarter. Assenagon Asset Management S.A. now owns 642,251 shares of the company's stock valued at $9,403,000 after purchasing an additional 311,107 shares during the last quarter. 92.89% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on ZYME. HC Wainwright lifted their target price on Zymeworks from $12.00 to $13.00 and gave the company a "neutral" rating in a report on Monday, March 10th. Citigroup lifted their price objective on Zymeworks from $18.00 to $19.00 and gave the company a "buy" rating in a research note on Friday, March 7th. Wells Fargo & Company increased their target price on shares of Zymeworks from $12.00 to $14.00 and gave the stock an "equal weight" rating in a research report on Thursday, December 19th. Lifesci Capital assumed coverage on shares of Zymeworks in a research report on Tuesday, March 11th. They set an "outperform" rating and a $30.00 price target on the stock. Finally, JPMorgan Chase & Co. raised shares of Zymeworks from a "neutral" rating to an "overweight" rating and set a $18.00 price objective for the company in a research report on Monday, December 16th. Two equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $21.00.

About Zymeworks

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.